Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Total Liabilities (2019 - 2025)

Historic Total Liabilities for Pharming (PHAR) over the last 7 years, with Q3 2025 value amounting to $465.8 million.

  • Pharming's Total Liabilities rose 1150.6% to $465.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $465.8 million, marking a year-over-year increase of 1150.6%. This contributed to the annual value of $392.2 million for FY2024, which is 1383.37% down from last year.
  • As of Q3 2025, Pharming's Total Liabilities stood at $465.8 million, which was up 1150.6% from $438.4 million recorded in Q2 2025.
  • Over the past 5 years, Pharming's Total Liabilities peaked at $420.4 billion during Q1 2021, and registered a low of $393671.3 during Q4 2021.
  • For the 5-year period, Pharming's Total Liabilities averaged around $44.9 billion, with its median value being $416.6 million (2023).
  • Examining YoY changes over the last 5 years, Pharming's Total Liabilities showed a top increase of 9542692.01% in 2022 and a maximum decrease of 9990.83% in 2022.
  • Over the past 5 years, Pharming's Total Liabilities (Quarter) stood at $393671.3 in 2021, then soared by 97117202.26% to $382.3 billion in 2022, then crashed by 99.88% to $455.2 million in 2023, then fell by 13.83% to $392.2 million in 2024, then grew by 18.77% to $465.8 million in 2025.
  • Its Total Liabilities stands at $465.8 million for Q3 2025, versus $438.4 million for Q2 2025 and $187.9 million for Q1 2025.